British biotech firm Relation Therapeutics said on Wednesday it entered into a research collaboration with GSK worth up to $110 million, aiming to generate human cellular datasets and train AI models for identifying potential new drug targets. The deal builds on an earlier partnership between the companies and reflects GSK's strategy to use AI to strengthen its drug pipeline.
Generating cellular datasets at scale
Under the agreement, Relation will produce large-scale datasets showing how human cells respond to genetic and drug interventions. The information will be used to train AI foundation models, including Relation's MORGAN platform. The work sits at the intersection of AI for Science & Research and pharmaceutical development, with the goal of improving the efficiency and success rate of drug discovery.
Building on an existing collaboration
The new deal expands a previous partnership between the two companies that focused on fibrotic diseases and osteoarthritis. GSK has been increasing investment in research and development, and the company sees AI as a way to identify new drug targets more effectively. The deal highlights the growing role of AI for Healthcare in early-stage drug research.
Why this matters for healthcare professionals
For those working in drug development and clinical research, the collaboration shows how AI-generated human cellular data can speed up the search for new drug targets. Modeling human biology at scale may reduce the time and cost of early-stage discovery, potentially bringing new therapies to patients faster. Healthcare professionals should track how these AI-trained models translate into actual pipeline candidates in the coming years.
Your membership also unlocks:
